Molecular imaging of atheroslerotic plaque with nuclear medicine techniques (Review)

International Journal of Molecular Medicine

Volumn 22, Issue 1, 2008, Pages 3-7

  Schillaci, Orazio ^a,b   Danieli, Roberta ^a   Padovano, Federico ^a   Testa, Angelo ^a   Simonetti, Giovanni ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Atherosclerosis; Molecular imaging; Nuclear medicine; Positron emission tomography; Single photon emission computed tomography

Indexed keywords

FLUORODEOXYGLUCOSE; INDIUM 111; INTERLEUKIN 2 TC 99M; IODINE 123; LIPOCORTIN 5 TC 99M; MATRIX METALLOPROTEINASE INHIBITOR; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG;

APOPTOSIS; ATHEROSCLEROTIC PLAQUE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG MONITORING; FEASIBILITY STUDY; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; ANIMAL; ATHEROSCLEROSIS; DIAGNOSTIC IMAGING; METHODOLOGY; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; DIAGNOSTIC IMAGING; HUMANS; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 52049106392     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.22.1.3     Document Type: Review

References (32)

1. Falk E: Pathogenesis of atherosclerosis. J Am Coll Cardiol 47: C7-C12, 2006.
2. Davies JR, Rudd JH and Weissberg PL: Molecular and metabolic imaging of atherosclerosis. J Nucl Med 45: 1898-1907, 2004.
3. 18Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol 50: 892-896, 2007.
4. Falk E, Shah PK and Fuster V: Atherothrombosis and thrombosis-prone plaques. In: Hurst's the Heart. Fuster V, Alexander RW, O'Rourke RA, et al (eds). 11th edition. McGraw-Hill, New York, pp1123-1139, 2004.
5. Naghavi M, Falk E, Hecht HS, et al: From vulnerable plaque to vulnerable patient - Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol 98: 2-15, 2006.
6. Kohler T: Imaging of carotid artery lesions: a surgeon's view. In: Syndromes of Atherosclerosis: Correlation of Clinical Imaging and Pathology. Fuster V (ed). Futura Publishing Co., Inc, Armonk, NY, pp277-289, 1996.
7. Ambrose J: Angiographic correlations of advanced coronary lesions in acute coronary syndromes. In: Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology. Fuster V (ed). Futura Publishing Co., Inc, Armonk, NY, pp105-122, 1996.
8. Dinsmore R: Imaging techniques in carotid and peripheral vascular disease. In: Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology. Fuster V (ed). Futura Publishing Co., Inc, Armonk, NY, pp277-289, 1996.
9. Schaar JA, Mastik F, Regar E, et al: Current diagnostic modalities for vulnerable plaque detection. Curr Pharm. Des 13: 995-1001, 2007.
10. Botvinick EH, Perini R, Bural G, et al: The aging of the heart and blood vessels: a consideration of anatomy and physiology in the era of computed tomography, magnetic resonance imaging, and positron emission tomographic imaging methods with special consideration of atherogenesis. Semin Nucl Med 37: 120-143, 2007.
11. Kolodgie FD, Petrov A, Virmani R, et al: Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation 108: 3134-3139, 2003.
12. Hartung D, Sarai M, Petrov A, et al: Resolution of apoptosis in atherosclerotic plaque by dietary modification and statin therapy. J Nucl Med 46: 2051-2056, 2005.
13. Johnson LL, Schofield L, Donahay T, et al: 99mTc-annexin V imaging for in vivo detection of atherosclerotic lesions in porcine coronary arteries. J Nucl Med 46: 1186-1193, 2005.
14. Kietselaer BL, Hofstra L, Dumont EA, et al: The role of labeled Annexin A5 in imaging of programmed cell death. From animal to clinical imaging. Q J Nucl Med 47: 349-361, 2003.
15. Iuliano L, Signore A, Vallabajosula S, et al: Preparation and biodistribution of 99m-technetium labelled oxidized LDL in man. Atherosclerosis 126: 131-141, 1996.
16. Schäfers M, Riemann B, Kopka K, et al: Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 109: 2554-2559, 2004.
17. Signore A, Chianelli M, D'Alessandria C, et al: Receptor targeting agents for imaging inflammation/infection: where are we now? Q J Nucl Med Mol Imaging 50: 236-242, 2006.
18. Annovazzi A, D'Alessandria C, Bonanno E, et al: Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes. Eur J Nucl Med Mol Imaging 33: 474-482, 2006.
19. Pauwels EK, Ribeiro MJ, Stoot JH, et al: FDG accumulation and tumor biology. Nucl Med Biol 25: 317-322, 1998.
20. 18F FDG Uptake in the large arteries: A correlation study with the atherogenic risk factors. Semin Nucl Med 32: 70-76, 2002.
21. 18F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 45: 1245-1250, 2004.
22. 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med 47: 1845-1850, 2006.
23. 18F]-fluorodeoxyglucose positron emission tomography. Circulation 105: 2708-2711, 2002.
24. 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 48: 1818-1824, 2006.
25. 18F-FDG PET/CT. J Nucl Med 45: 1816-1821, 2004.
26. 18F-FDG uptake with vascular calcification. J Nucl Med 46: 1278-1284, 2005.
27. Tatsumi M, Cohade C, Nakamoto Y, et al: Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology 229: 831-837, 2003.
28. Budoff MJ, Shavelle DM, Lamont DH, et al: Usefulness of electron beam computed tomography scanning for distinguishing ischemic from nonischemic cardiomyopathy. J Am Coll Cardiol 32: 1173-1178, 1998.
29. Tahara N, Kai H, Nakaura H, et al: The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxy-glucose-positron emission tomography. Eur Heart J 28: 2243-2248, 2007.
30. 18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 49: 1533-1539, 2007.
31. Tahara N, Kai H, Ishibashi M, et al: Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 48: 1825-1831, 2006.
32. 18F-choline images murine atherosclerotic plaques ex vivo. Arterioscler Thromb Vasc Biol 260: 584-589, 2006.